Logo

American Heart Association

  32
  0


Final ID:

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

  • Mahfoud, Felix  ( University Hospital Basel , Basel , Switzerland )
  • Author Disclosures:
    Felix Mahfoud: DO have relevant financial relationships ; Consultant:Ablative Solutions, Medtronic and ReCor Medical.:Past (completed) ; Speaker:Ablative Solutions, Astra-Zeneca, Inari, Medtronic, Merck, Novartis, Philips and ReCor Medical.:Past (completed) ; Researcher:Ablative Solutions, Medtronic and ReCor Medical.:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

TCT at AHA: Renal Denervation for Hypertension: What Comes Next?

Monday, 11/10/2025 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts from these authors:
National Estimates of Patient Eligibility for Renal Denervation Therapy Post-FDA Approval

Watson Nathan, Earle William, Kandzari David, Kirtane Ajay, Mahfoud Felix, Cluett Jennifer, Krawisz Anna, Juraschek Stephen, Secemsky Eric

Alternative Renal Denervation Devices – From Ablative Solutions to Verve

Kandzari David, Kirtane Ajay, Mahfoud Felix

You have to be authorized to contact abstract author. Please, Login
Not Available